| Author | Avelino-Silva, Vivian | pt_BR |
| Author | Miyaj, Karina Takesaki | pt_BR |
| Author | Mathias, Augusto | pt_BR |
| Author | Costa, Dayane Alves | pt_BR |
| Author | Dias, Juliana Zanatta de Carvalho | pt_BR |
| Author | Lima, Sheila Barbosa | pt_BR |
| Author | Simoes, Marisol | pt_BR |
| Author | Freire, Marcos S. | pt_BR |
| Author | Caiaffa-Filho, Helio H. | pt_BR |
| Author | Hong, Marisa A. | pt_BR |
| Author | Lopes, Marta H. | pt_BR |
| Author | Sartori, Ana M. | pt_BR |
| Author | Kallas, Esper Georges | pt_BR |
| Access date | 2019-03-20T19:34:21Z | |
| Available date | 2019-03-20T19:34:21Z | |
| Document date | 2016 | |
| Citation | AVELINO-SILVA, Vivian Iida et al. CD4/CD8 Ratio Predicts Yellow Fever Vaccine-Induced Antibody Titers in Virologically Suppressed HIV-Infected Patients. Journal Of Acquired Immune Deficiency Syndromes, Hagerstown, v. 71, n. 2, p.189-195, 2016. | pt_BR |
| ISSN | 1944-7884 | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/32186 | |
| Language | eng | pt_BR |
| Rights | open access | pt_BR |
| Title | CD4/CD8 ratio predicts yellow fever vaccine-induced antibody titers in virologically suppressed HIV-infected patients | en |
| Type | Article | pt_BR |
| DOI | 10.1097/QAI.0000000000000845 | |
| Abstract | BACKGROUND: Yellow fever vaccine (YFV) induces weaker immune responses in HIV-infected individuals. However, little is known about YFV responses among antiretroviral-treated patients and potential immunological predictors of YFV response in this population. METHODS: We enrolled 34 antiretroviral therapy (ART)-treated HIV-infected and 58 HIV-uninfected adults who received a single YFV dose to evaluate antibody levels and predictors of immunity, focusing on CD4(+) T-cell count, CD4(+)/CD8(+) ratio, and Human Pegivirus (GBV-C) viremia. Participants with other immunosuppressive conditions were excluded. RESULTS: Median time since YFV was nonsignificantly shorter in HIV-infected participants than in HIV-uninfected participants (42 and 69 months, respectively, P = 0.16). Mean neutralizing antibody (NAb) titers was lower in HIV-infected participants than HIV-uninfected participants (3.3 vs. 3.6 log10mIU/mL, P = 0.044), a difference that remained significant after adjustment for age, sex, and time since vaccination (P = 0.024). In HIV-infected participants, lower NAb titers were associated with longer time since YFV (rho: -0.38, P = 0.027) and lower CD4(+)/CD8(+) ratio (rho: 0.42, P = 0.014), but not CD4(+) T-cell count (P = 0.52). None of these factors were associated with NAb titers in HIV-uninfected participant. GBV-C viremia was not associated with difference in NAb titers overall or among HIV-infected participants. CONCLUSIONS: ART-treated HIV-infected individuals seem to have impaired and/or less durable responses to YFV than HIV-uninfected individuals, which were associated with lower CD4(+)/CD8(+) ratio, but not with CD4(+) T-cell count. These results supports the notion that low CD4(+)/CD8(+) ratio, a marker linked to persistent immune activation, is a better indicator of functional immune disturbance than CD4(+) T-cell count in patients with successful ART. | en |
| Affilliation | Faculdade de Medicina da Universidade de São Paulo. Departamento de Doenças Infecciosas e Parasitárias. São Paulo, SP, Brasil. | pt_BR |
| Affilliation | Faculdade de Medicina da Universidade de São Paulo. Departamento de Doenças Infecciosas e Parasitárias. São Paulo, SP, Brasil. | pt_BR |
| Affilliation | Faculdade de Medicina da Universidade de São Paulo. Divisão de Clínica de Imunologia e Alergia. São Paulo, SP, Brasil. | pt_BR |
| Affilliation | Faculdade de Medicina da Universidade de São Paulo. Divisão de Clínica de Imunologia e Alergia. São Paulo, SP, Brasil. | pt_BR |
| Affilliation | Faculdade de Medicina da Universidade de São Paulo. Divisão de Clínica de Imunologia e Alergia. São Paulo, SP, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Instituto Adolfo Lutz. São Paulo, SP, Brasil. | pt_BR |
| Affilliation | Instituto Adolfo Lutz. São Paulo, SP, Brasil / Faculdade de Medicina da Universidade de São Paulo. Divisão de Clínica de Imunologia e Alergia. São Paulo, SP, Brasil. | pt_BR |
| Affilliation | Faculdade de Medicina da Universidade de São Paulo. Departamento de Doenças Infecciosas e Parasitárias. São Paulo, SP, Brasil. | pt_BR |
| Affilliation | Faculdade de Medicina da Universidade de São Paulo. Departamento de Doenças Infecciosas e Parasitárias. São Paulo, SP, Brasil. | pt_BR |
| Affilliation | Faculdade de Medicina da Universidade de São Paulo. Departamento de Doenças Infecciosas e Parasitárias. São Paulo, SP, Brasil / Faculdade de Medicina da Universidade de São Paulo. Divisão de Clínica de Imunologia e Alergia. São Paulo, SP, Brasil. | pt_BR |
| Subject | Yellow fever vaccine | en |
| Subject | Yellow fever neutralizing antibodies | en |
| Subject | HIV | en |
| Subject | CD4+/CD8+ ratio | en |
| Subject | Immune activation | en |
| xmlui.metadata.dc.subject.ods | 03 Saúde e Bem-Estar | |
